Efficacy and Safety of 4-aminopyridine on Cognitive Performance and Motor Function of Patients With Multiple Sclerosis
Status:
Completed
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
Twenty four relapsing-remitting multiple sclerosis (RRMS) patients over the age of 18, with
similar degree of disability, and with an evolution of at last 6 months, who are in
first-line immunomodulatory therapy and have a stable disease (no more than one outbreak per
year) will be included in the present study. Patients will be administered a
neuropsychological test battery selected for this study and divided into two sessions of one
and a half-hour each. Emotional state will be assessed with the Beck Depression Inventory in
a different session. Cognitive impairment is defined as the alteration of two or more
neuropsychological tests. Patients will be divided randomly into two groups where one will
receive placebo and the other one 4-Aminopyridine (4-AP) for a period of 22 weeks in
increasing doses.